UCARTCS1A is a SLAMF7 targeted allogeneic (donor-derived) CAR T-cell therapy being developed for multiple myeloma patients.
May 5, 2023: Cellectis has given up on its multiple myeloma CAR-T candidate UCARTCS1. With the phase 1 clinical trial two years behind schedule, and heavy investment needed to accelerate enrollment, the off-the-shelf cell therapy specialist is stopping the study and focusing its resources on three other candidates. Learn more
| SparkCures ID | 338 |
|---|---|
| Developed By | Cellectis S.A. |
| Generic Name | UCARTCS1A |
| Treatment Classifications | |
| Treatment Targets |